Published in Nat Rev Clin Oncol on March 13, 2012
CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response. Oncotarget (2014) 0.85
Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer. Breast Cancer (Auckl) (2016) 0.82
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers (Basel) (2017) 0.77
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet (2012) 7.31
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol (2011) 7.10
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol (2010) 4.94
Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev (2007) 4.11
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 2.72
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res (2010) 3.04
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res (2005) 2.73
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer (2009) 2.60
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res (2013) 2.09
What is triple-negative breast cancer? Eur J Cancer (2008) 2.01
Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst (2014) 1.96
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest (2008) 1.80
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg (2006) 1.69
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics (2011) 1.67
Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res (2010) 1.56
Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol (2010) 1.55
Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist (2013) 1.49
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg (2009) 1.46
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat (2012) 1.43
The interaction of post-traumatic growth and post-traumatic stress symptoms in predicting depressive symptoms and quality of life. Psychooncology (2008) 1.37
The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer (2010) 1.37
Women's experiences with genomic testing for breast cancer recurrence risk. Cancer (2010) 1.29
Women's interest in gene expression analysis for breast cancer recurrence risk. J Clin Oncol (2007) 1.27
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat (2012) 1.23
Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol (2011) 1.22
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal (2014) 1.20
Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res (2014) 1.19
An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res (2009) 1.19
Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol (2008) 1.18
Gene expression profiling in breast cancer. Curr Opin Oncol (2007) 1.15
Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. J Natl Compr Canc Netw (2008) 1.12
Molecular profiling in breast cancer. Rev Endocr Metab Disord (2007) 1.10
Knowledge of genomic testing among early-stage breast cancer patients. Psychooncology (2011) 1.08
Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy. Cancer Epidemiol Biomarkers Prev (2007) 1.08
Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res (2010) 1.07
Quantifying the recruitment challenges with couple-based interventions for cancer: applications to early-stage breast cancer. Psychooncology (2009) 1.06
Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res (2007) 1.04
Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res (2012) 1.03
Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol (2009) 0.99
Improving communication of breast cancer recurrence risk. Breast Cancer Res Treat (2011) 0.98
When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy. Breast Cancer Res Treat (2008) 0.97
PARP and cancer--if it's broke, don't fix it. N Engl J Med (2011) 0.96
Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. Mol Carcinog (2008) 0.96
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol (2008) 0.94
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res (2011) 0.93
Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer (2006) 0.93
Clonal evolution of lymphoblastoid cell lines. Lab Invest (2006) 0.93
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat (2012) 0.92
Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer. Oncol Rep (2008) 0.92
Clinical trials in triple negative breast cancer. Breast Dis (2010) 0.92
The management of early-stage and metastatic triple-negative breast cancer: a review. Hematol Oncol Clin North Am (2013) 0.92
Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. J Clin Oncol (2009) 0.91
Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. Radiology (2007) 0.91
Improving endocrine therapy for breast cancer: it's not that simple. J Clin Oncol (2012) 0.91
Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic. Ann Surg Oncol (2006) 0.90
Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer. Med Image Comput Comput Assist Interv (2006) 0.90
Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. Breast Cancer Res Treat (2015) 0.89
Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Res Treat (2015) 0.88
Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res (2007) 0.88
Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunol Immunother (2004) 0.87
Radiation clastogenesis and cell cycle checkpoint function as functional markers of breast cancer risk. Carcinogenesis (2006) 0.87
Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. Exp Mol Pathol (2013) 0.86
Understanding how breast cancer patients use risk information from genomic tests. J Behav Med (2012) 0.86
The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. Ann Surg Oncol (2014) 0.86
Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol (2007) 0.85
Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin Breast Cancer (2010) 0.83
Defining the expressed breast cancer kinome. Cell Res (2012) 0.82
Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat (2014) 0.82
Current treatment paradigms for the management of patients with brain metastases. Neurosurgery (2005) 0.81
Engaging in health behaviors to lower risk for breast cancer recurrence. PLoS One (2013) 0.81
Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. Am J Surg (2005) 0.81
Reporting of race and ethnicity in breast cancer research: room for improvement. Breast Cancer Res Treat (2009) 0.80
Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate. Am Surg (2011) 0.79
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat (2015) 0.78
Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer. Oncologist (2012) 0.78
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat (2014) 0.78
Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer. Oncology (Williston Park) (2006) 0.77
The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies. J Biopharm Stat (2015) 0.76
Neoadjuvant trials of human epidermal growth factor receptor 2 targeting: how many drugs do we need? J Clin Oncol (2012) 0.76
High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. Am J Surg (2004) 0.76
Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. PLoS Med (2017) 0.75
Adjuvant systemic therapy in young women. Breast Dis (2006) 0.75
Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenet Genomics (2017) 0.75